A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer
Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Urologic Neoplasms, Renal Pelvis Neoplasms, Urothelial Cancer, Ureteral Neoplasms, Urethral Neoplasms, ASG-22ME, ASG-22CE, Antibody-drug conjugate, Antineoplastic agents, CPI, Enfortumab vedotin, MIBC, Locally advanced urothelial cancer, Cisplatin, Drug therapy, Carboplatin, Metastatic urothelial cancer, Nectin-4, Gemcitabine, Muscle invasive bladder cancer, Checkpoint Inhibitors, Pembrolizumab, PD-1 inhibitor, Neoplasms, Pelvic Neoplasms, enfortumab vedotin (EV), EV + Pembrolizumab in cisplatin-ineligible 1L and in 2L, EV + Pembrolizumab in cisplatin-ineligible 1L, Enfortumab Vedotin + Cisplatin in 1L, Enfortumab Vedotin + Carboplatin in 1L, Enfortumab Vedotin + Platinum + Pembrolizumab in 1L, Enfortumab vedotin in MIBC neoadjuvant setting, Enfortumab vedotin in MIBC in perioperative setting
Lead Scientist at UCSF
- Terence Friedlander
I am a clinical and translational medical oncologist with a focused on urologic cancers, specifically cancers of the bladder, prostate, and kidney. I am also the Chief of the ZSFG Division of Hematology and Oncology. My research is focused on understanding the basic biology of urologic and other malignancies and in developing novel therapeutic ways to treat disease.
- accepting new patients
- Start Date
- Completion Date
- Astellas Pharma Global Development, Inc.
- Phase 1/2 research study
- Study Type
- Expecting 457 study participants
- Last Updated